Elena Lastraioli

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Annarosa Arcangeli · 2 shared papers, 2015–2023 · strength 0.19
   • Paper Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Du… DOI 10.3390/cancers15072013↗
   • Paper hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. DOI 10.1038/bjc.2015.28↗
2. Roberto Coppola · 2 shared papers, 2015–2023 · strength 0.19
   • Paper Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Du… DOI 10.3390/cancers15072013↗
   • Paper hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. DOI 10.1038/bjc.2015.28↗
3. Claudia Duranti · 1 shared paper, 2023 · strength 0.16
   • Paper Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Du… DOI 10.3390/cancers15072013↗
4. Tiziano Lottini · 1 shared paper, 2023 · strength 0.16
   • Paper Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Du… DOI 10.3390/cancers15072013↗
5. Stefano Coppola · 1 shared paper, 2023 · strength 0.16
   • Paper Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Du… DOI 10.3390/cancers15072013↗
6. Alessandro Coppola · 1 shared paper, 2023 · strength 0.16
   • Paper Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Du… DOI 10.3390/cancers15072013↗
7. Vincenzo La Vaccara · 1 shared paper, 2023 · strength 0.16
   • Paper Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Du… DOI 10.3390/cancers15072013↗
8. Sagar S. Manoli · 1 shared paper, 2015 · strength 0.04
   • Paper hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. DOI 10.1038/bjc.2015.28↗
9. Lapo Bencini · 1 shared paper, 2015 · strength 0.04
   • Paper hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. DOI 10.1038/bjc.2015.28↗
10. Domenico Borzomati · 1 shared paper, 2015 · strength 0.04
    • Paper hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. DOI 10.1038/bjc.2015.28↗
11. Angelica Sette · 1 shared paper, 2015 · strength 0.04
    • Paper hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. DOI 10.1038/bjc.2015.28↗
12. Gennaro Nappo · 1 shared paper, 2015 · strength 0.04
    • Paper hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. DOI 10.1038/bjc.2015.28↗
13. Francesco Di Costanzo · 1 shared paper, 2015 · strength 0.04
    • Paper hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. DOI 10.1038/bjc.2015.28↗
14. Daniele Santini · 1 shared paper, 2015 · strength 0.04
    • Paper hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. DOI 10.1038/bjc.2015.28↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.